Home

News: Jul 2021

node teaser

Changes to the use of palivizumab to protect at-risk children from winter respiratory virus

20 July 2021

Respiratory syncytial virus (RSV) usually occurs for a few weeks in the winter and is the most common cause of infections in the airways and lungs (lower respiratory tract infection) in children. For most children, RSV causes only mild illness that doesn’t need treatment. However, some children are at risk of severe infection that may need treatment in hospital.